Medically reviewed by David Ozeri, MD C3G (Complement 3 Glomerulopathy) and IC-MPGN (Immune Complex Membranoproliferative ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but ...

Pegcetacoplan has been approved for the treatment of C3 glomerulopathy or primary immune complex membranoproliferative ...

I’m excited to now have a highly effective therapy for a broad range of patients living with C3G and primary IC-MPGN,” said ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

The FDA has approved Empaveli for the treatment of adult and pediatric patients aged 12 years and older with C3G or primary ...

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts. On July 29, Apellis announced that the US FDA approved EMPAVELI (pegcetacoplan) as the ...

The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary ...

C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are two diseases that have a ...

DelveInsight's“ IC-MPGN – Market Insights, Epidemiology, and Market Forecast – 2034 ” delivers a deep dive analysis of the evolving disease landscape, highlighting epidemiological patterns ...

Approximately 50% of people living with C3G and IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis. 1 ...